The clinical pharmacology of therapeutic monoclonal antibodies

Drug Development Research

Volumn 61, Issue 3, 2004, Pages 108-120

  Roskos, Lorin K ^a   Davis, C Geoffrey ^a   Schwab, Gisela M ^a  

^a Abgenix Inc   (United States)

Author keywords

Immunogenicity; Monoclonal antibody; Pharmacokinetics; Pharmacology; Safety

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; CHIMERIC ANTIBODY; DACLIZUMAB; EFALIZUMAB; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; HUMAN MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; ORTHOCLONE OKT 3; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; ASTHMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CROHN DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; PERCUTANEOUS CORONARY INTERVENTION; PHAGE DISPLAY; PSORIASIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; TRANSGENIC MOUSE; VIRUS INFECTION;

EID: 3843133934     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10346     Document Type: Review

References (105)

1. Abbott Laboratories. 2002. Adalimumab prescribing information. North Chicago, IL: Abbot Laboratories.
2. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. 1998. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58:485-490.
3. Akamizu T, Moriyama K, Miura M, Saijo M, Matsuda F, Nakao K. 1999. Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Grave's disease: epitope and binding study of two stimulatory TSHRAbs. Endocrinology 140:1594-1601.
4. Andrechek ER, Hardy WR, Girgis-Gabardo AA, Perry RL, Butler R, Graham FL, Kahn RC, Rudnicki MA, Muller WJ. 2002. ErbB2 is required for muscle spindle and myoblast cell survival. Mol Cell Biol 22:4714-4722.
5. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608.
6. Baselga J. 2001. Clinical trials of herceptin (Trastuzumab). Eur J Cancer 37(Suppl 1):S18-S24.
7. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. 1996. Phase II study of weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody in patients with HER2/Neu-overex-pressing metastatic breast cancer. J Clin Oncol 14:737-744.
8. Brambell FWR, Hemmings WA, Morris IG. 1964. A theoretical model of gamma-globulin catabolism. Nature 203:1352-1355.
9. Burk ML, Matuszewski KA. 1997. Muromonab-CD3 and antithymocyte globulin in renal transplantation. Ann Pharmacother 31:1370-1377.
10. Bush RK. 2002. The use of Anti-IgE in the treatment of allergic asthma. Med Clin N Am 86:1113-29.
11. Carswell CI. Plosker GL, Wagstaff AJ. 2001. Daclizumab: a review of its use in the management of organ transplantation. BioDrugs 15:745-773.
12. Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129.
13. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758.
14. Cather JC, Cather JC, Menter A. 2003. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 3:361-370.
15. Chen TT, Tao MH, Levy R. 1994. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating Factor. J Immunol 153:4775-4787.
16. Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446.
17. Cook-Bruns N. 2001. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61(Suppl 2):58-66.
18. Curnow RT. 1997. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 45:210-215.
19. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. 2002. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99:2054-2059.
20. D'Amato G. 2003. Therapy of allergic bronchial asthma with omalizumab: an anti-IgE monoclonal antibody. Expert Opin Biol Ther 3:371-376.
21. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74:288-294.
22. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, Lencer WI. 1999. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104:903-911.
23. Dillman RO. 1990. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunocon Radiopharm 3:1-15.
24. Dyer MJ. 1999. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26:52-57.
25. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. 1989. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73:1431-1439.
26. Einhorn MS, Granoff DM, Nahm MH, Quinn A, Shackelford PG. 1987. Concentrations of antibodies in paired maternal and infant sera: relationship to IgG subclass. J Pediatr 111:783-788.
27. Flynn JM, Byrd JC. 2000. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12:574-581.
28. Figlin RA, Belldegrun AS, Crawford J, Lohner M, Roskos L, Yang XD, Foon KA, Schwab G, Weiner L. 2002. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 21:10a.
29. Foster RH, Wiseman LR. 1998. Abciximab. an updated review of its use in ischaemic heart disease. Drugs 56:629-665.
30. Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD. 1994. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1:667-669.
31. Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ. 1991. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 39:141-148.
32. Genentech. 2003. Omalizumab prescribing information. South San Francisco, CA: Genentech, Inc.
33. Ghetie V, Ward ES. 2002. Transcytosis and catabolism of antibody. Immunol Res 25:97-113.
34. Gibson A. 2002. Iodine-131 Tositumomab(Bexxar) in relapsed/refractory non-Hodgkin's lymphoma: update from the 2001 American Society of Hematology Meeting. Clin Lymph 2:209-211.
35. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. 2001. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92:406-13.
36. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, Batra SK, 2000. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 60:6964-6971.
37. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK. 1999. Overview of the clinical development of Rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26:66-73.
38. Grillo-Lopez AJ, Dallaire BK, McClure A, Weaver R, Varns C, Wei A, Allen R, Lee D, Shen D, Leonard J, Multani P, White CA. 2001. Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2:301-311.
39. Hainsworth JD. 2000. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 5:376-84.
40. Hanes J, Pluckthun A. 1997. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94:4937-4942.
41. Harris KA, Wahsington CB, Lieberman G, Lu JF, Mass R, Bruno R. 2002. A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol 21:123a.
42. Hendrix CS, de Leon C, Dillman RO, 2002. Radioimmunotherapy for non-Hodgkins lymphoma with Yttrium 90 Ibritumomab Tiuxetan. Clin J Oncol Nurs 6:144-148.
43. Hooks MA, Wade CS, Millikan WJ Jr. 1991. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11:26-37.
44. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R. 1993. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann NY Acad Sci 690:385-387.
45. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246:1275-1281.
46. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954-960.
47. Junghans RP. 1997. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16:29-57.
48. Juweid ME. 2002. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 43:1507-1529.
49. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. 2003. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65.
50. Klingbeil C, Hsu DH. 1999. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol 27:1-3.
51. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
52. Krueger GG, ABX-IL8 Psoriasis Study Group. 2002. Clinical results of ABX-IL8, a fully human antibody used in the treatment of moderate to severe psoriasis. 60th Annual Meeting of the American Academy of Dermatology. New Orleans, LA. Abstract P26.
53. Kuroiwa Y, Tomizuka K, Shinohara T, Kazuki Y, Yoshida H, Ohguma A, Yamamoto T, Tanaka S, Oshimura M, Ishida I. 2000. Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts. Nat Biotechnol 18:1086-1090.
54. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. 1994. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1:365-372.
55. Leyland-Jones B. 2001. Dose scheduling: Herceptin. Oncology 61(Suppl 2):31-36.
56. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378.
57. Linenberger ML, Maloney DG, Bernstein ID. 2002. Antibody-directed therapies for hematological malignancies. Trends Mol Med 8:69-76.
58. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG, 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856-859.
59. Maloney DG. 2001. Mechanism of action of Rituximab. Anticancer Drugs 12(Suppl 2):S1-S4.
60. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552-554.
61. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. 2001. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 166:6112-6117.
62. Medical Letter on Drugs and Therapeutics. 2003. Adalimumab (Humira) for rheumatoid arthritis. Med Lett Drugs Ther 45:25-27.
63. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 15:146-156.
64. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851-6855.
65. Moser MA. 2002. Options for induction immunosuppression in liver transplant recipients. Drugs 62:995-1011.
66. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. 2003. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 37:1256-1265.
67. Ober RJ, Radu CG, Ghetie V, Ward ES. 2001. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551-1559.
68. Onrust SV, Wiseman LR. 1999. Basiliximab. Drugs 57:207-213.
69. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. 1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671.
70. Pollack P, Groothuis JR. 2002. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J Infect Chemother 8:201-206.
71. Presta LG. 2002. Engineering antibodies for therapy. Curr Pharm Biotechnol 3:237-256.
72. Rau R. 2002. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61(Suppl 2):ii7O-ii73.
73. Renard C, Grene-Lerouge N, Beau N, Baud F, Scherrmann JM. 1997. Pharmacokinetics of digoxin-specific fab: effects of decreased renal function and age. Br J Clin Pharmacol 44:135-138.
74. Reynolds NA, Wagstaff AJ. 2004. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs 64:109-118.
75. Riechmann L, Clark M, Waldmann H, Winter G. 1988. Reshaping human antibodies for therapy. Nature 332:323-327.
76. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. 2003. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101:466-468.
77. Sandborn WJ, Hanauer SB. 2002. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 97:2962-2972.
78. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. 2001. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088-1094.
79. Schaumann W, Kaufmann B, Neubert P, Smolarz A. 1986. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 30:527-533.
80. Schneider H, Chaovapong W, Matthews DJ, Karkaria C, Cass RT, Zhan H, Boyle M, Lorenzini T, Elliott SG, Giebel LB. 1997. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 89:473-482.
81. Schneider JV, Chang AY, Rocco TP. 2001. Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heart. Semin Oncol 28:18-26.
82. Schneider JW, Chang AY, Garratt A. 2002. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 29:22-28.
83. Schwartz G, Dutcher J, Vogeizang N, Gollob J, Thompson J, Bukowski RM, Figlin RA, Lohner M, Roskos L, Hwang CC, Foon KA, Schwab G, Rowinsky EK. 2002. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 21:24a.
84. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ. 2003. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639-1647.
85. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740.
86. Sievers EL, Linenberger M. 2001. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 13:522-527.
87. Sissi C, Aiyar J, Boyer S, Depew K, Danishefsky S, Crothers DM. 1999. Interaction of calicheamicin gamma1(I) and its related carbohydrates with DNA-protein complexes. Proc Natl Acad Sci USA 96:10643-10648.
88. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, Lencer WI. 2002. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 196:303-310.
89. St Clair EW 2002. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 61(Suppl 2):ii67-ii69.
90. Stein KE. 2002. Immunogenicity: concepts/issues/concerns. Biologics 2000: comparability of biotechnology products. Basel: S. Karger, p 15-23.
91. Su CG, Judge TA, Lichtenstein GR. 2001. The role of biological therapy in inflammatory bowel disease. Drugs Today (Barc.) 37:121-133.
92. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Braden GA. 2001. Abciximab readministration: results of the ReoPro readministration registry. Circulation 104:870-875.
93. Trang JM. 1992 Pharmacokinetics and Metabolism of Therapeutic and Diagnostic Antibodies. In: Ferraiolo BL, Mohler MA, Gloff CA, Editors. Protein Pharmacokinetics and Metabolism. New York: Plenum Press. pp 223-270.
94. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305.
95. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:1774-1785.
96. Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, Damaraju L, Schaible T, Maini RN, Tcheng JE. 2003. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 112:37-53.
97. Waldmann TA, Strober W, Blaese RM. 1970 Variations in the metabolism of immunoglobulins measured by turnover rates. Immunoglobulins: biological aspects and clinical uses. Washington, DC: National Academy of Sciences. P 33-51.
98. Ward ES, Zhou J, Ghetie V, Ober RJ. 2003. Evidence to support the cellular: mechanism involved in serum IgG homeostasis in humans. Int Immunol 15:187-195.
99. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, Coblyn JS, Maier AL, Spreen WR, Manna VK, et al. 1995. Campath-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 38:1589-1594.
100. Weiner LM. 1999. Monoclonal antibody therapy of cancer. Semin Oncol 26:43-51.
101. Welt S, Ritter G, Williams C, Jr., Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE. 2003. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 9:1338-1346.
102. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. 1999. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymhocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2BS). Blood 94:2217-2224.
103. Wurster U, Haas J. 1994. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 57(Suppl):21-25.
104. Zein N, Sinha AM, McGahren WJ, Ellestad GA. 1988. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198-1201.
105. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, Lencer WI, Blumberg RS. 2001. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 166:3266-3276.